Tempramed Technologies Ltd. · CSE:VIVI
Tempramed Technologies — Investor Presentation (September 2026)
19 slides from Tempramed Technologies's investor presentation, September 2026
Slide 1: Protection & Connectivity to ALL Injection Devices for Home Care
Protection & Connectivity to ALL Injection Devices for Home Care Wearables & AI Platforms As Seen On DR. PHIL TEM PRAM ED INTRODUCTION · Sep 2026 Watch Medication reminder & temperature protector www.tempramed.com
Slide 2: The opportunity — 4 mega trends converge on connected, temperature-protected injectables
DIGITAL HEALTH · MARKET MOMENTUM The opportunity — 4 mega trends converge on connected, temperature-protected injectables Each one independently expands demand for protected, connected injectable medication. 01 THE GLP-1 & PEPTIDE BOOM 02 CARE IS MOVING INTO THE HOME WHY TEMPRAMED GAINS FROM ALL FOU
Slide 3: The winning platform needs VIVI by TempraMed for injectables
STRATEGIC OPPORTUNITY The winning platform needs VIVI by TempraMed for injectables BIG TECH M EDICAL DEVICE PHARM A Apple Google Dexcom Abbott Lilly Novo Nordisk Samsung Huawei Medtronic Roche Already crossing sector lines to find it: Lilly × Oura Abbott × WHOOP Samsung × Xealth Novo Nordisk × Withi
Slide 4: What is TempraMed?
WHAT IS TEMPRAMED? What is TempraMed? TempraMed’s products are essential for hundreds of millions of injection pens and vials used every day — providing hassle-free temperature shield and data connectivity. 150,000~ UNITS SOLD Advanced temperature protection and injection reminders for injectable me
Slide 5: Unique patented & validated technology platform
TECHNOLOGY Unique patented & validated technology platform Combining features used in spacecraft, avionics and medical cryotherapy. 1 Proprietary thermal structure – 11 granted patents Patented architecture engineered around the medication cartridge. 2 Exceptional “space-grade” thermal insulation In
Slide 6: Existing product portfolio
PRODUCT PORTFOLIO Existing product portfolio NEW NEW VIVI Cap VIVI Cap Smart VIVI Med VIVI Epi The core original product providing validated Next-generation connected device integrated Expanded protective solution designed for Expanded marketing initiative for epinephrine temperature protection for
Slide 7: VIVI “Smart” platform for digital health
DIGITAL HEALTH VIVI “Smart” platform for digital health Launched December 2025 — from hardware to a recurring data layer. VIVI smart devices protect medications and harness data analysis, enabling remote management of medical conditions and adherence to therapy. AUTOMATIC TRACKING VOICE RECOGNITION
Slide 8: Product portfolio: new products
PRODUCT PORTFOLIO Product portfolio: new products Making every injection device connected and temperature protected. VIVI Med Smart VIVI Cool 8c VIVI Box / VIVI Box8c & Smart versions Temperature shield and connectivity for medication injectors Hassle-free keeping of medications refrigerated for up
Slide 9: Path to reimbursement - healthcare savings for payors
HEALTHCARE SAVINGS Path to reimbursement - healthcare savings for payors US base case · diabetes example HEALT HCARE UT I LI ZAT I ON I MPACT Severe event reduction DKA prevention ($29,981/event) & severe hypoglycemia $890 ($1,700/event) 2–3 2–3 0.5–1 HbA1c improvement $2,225 $550 Doctor visits redu
Slide 10: Demand is already there — Ready to Scale
MARKET TRACTION Demand is already there — Ready to Scale Six-figure installed base, an active user record, and four independent routes to market — no single-channel dependency. 150,000+ 200,000+ Four independent routes to market Each channel can scale on its own — no dependence on any single partner
Slide 11: Why TempraMed Will own this category
WHY TEMPRAMED WINS – TEMPERATURE CONTROL PERSPECTIVE Why TempraMed Will own this category Only validated solution FEATURE · COMPETITIVE LANDSCAPE VIVI CAP TRADITIONAL COOLERS No other product addresses the “last-mile” storage gap. TempraMed owns the patent on this space-grade insulation technology.
Slide 12: One universal layer under every injectable — no one else can say that
WHY TEMPRAMED WINS – DATA PERSPECTIVE One universal layer under every injectable — no one else can say that Every existing smart-pen solution is welded to one brand’s pen. VIVI is the only layer built for any pen, any vial, any auto-injector — plus the temperature shield none of them have. T O DAY —
Slide 13: Current platform tracks everything — except the injectables
FOR PLATFORM PARTNERS – VIVI PRODUCTS OFFERING Current platform tracks everything — except the injectables Injectable medication use and integrity is the one clinical signal no wearable, ring or CGM can capture on its own. VIVI already closes it — for any pen, any vial, any brand. W H AT P LAT FOR M
Slide 14: Every step up the mountain leads to one summit
COMPANY STRATEGY Every step up the mountain leads to one summit A strategic partnership is where we are going. Portfolio, users, sales and profitability are how we climb there. THE SUMMIT STRATEGIC PARTNERSHIP 04 REACH WE ARE HERE PROFITABILITY 03 A self-funding business that supports SCALE SALES th
Slide 15: Experts and users both highly recommend
VALIDATION Experts and users both highly recommend HEALTHCARE PROFESSIONALS REAL RESULTS LEAD TO HAPPY CUSTOMERS 4.4 ★★★★½ 645 Amazon ratings · VIVI Cap “The VIVI Cap will be of particular benefit for my patients.” 50% of surveyed users already recommended VIVI Cap to a friend; a further 50% indicat
Slide 16: Experienced management team
TEAM Experienced management team ILAN COHEN RON NAGAR GABI KABAZO DANIEL SALOMON Founder & CEO CFO General Manager, America Executive Chairman Medical device serial entrepreneur 20+ years of experience in Ex Teva Executive,17 years at Teva. Served as Head Serial entrepreneur and Former and inventor.
Slide 17: Board / Advisors
TEAM Board / Advisors SUSAN ALPERT, MD, PhD JULIA BECKER JOHN SINCLAIR Chief Regulatory Advisor Board of Directors Board of Directors Former Director of Device Evaluation at 15 years experience in capital markets, Senior business strategist and advisor, a CPA the FDA, Senior VP Global Regulatory. in
Slide 18: Disclaimer
DISCLAIMER TempraMed Disclaimer The Presentation is not intended to provide, and should not be relied upon for, tax, legal, accounting or investment advice. You should consult your own attorneys, business advisers and tax advisers as to the investment and as to the tax, legal, accounting, business a
Slide 19: TempraMed
TempraMed Ron Nagar CHIEF EXECUTIVE OFFICER ron@tempramed.com www.tempramed.com CSE: VIVI · OTC QB : TMP TF · FS E : 9 D Y TempraMed · Introduction · Sept. 2026
TempraMed Technologies — Investor Presentation (September 2026) on 6ix